HLAB-002 of ANS-6637 for Alcohol Use Disorder
Alcohol Addiction | Mental Health & Behavioral Research
What is the purpose of this trial?
The primary objective of this study is to evaluate the effects of two different doses of ANS-6637, 200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day, and matched placebo, on alcohol cue-elicited alcohol craving during a human laboratory paradigm after 1 week of daily dosing among subjects with moderate to severe alcohol use disorder (AUD) as confirmed by the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5™).
- Ages21 years and older
- Trial withNational Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Start Date10/01/2019
- End Date07/31/2020
- Last Updated10/15/2019
- Study HIC#2000025902